JP2005535562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535562A5 JP2005535562A5 JP2003562155A JP2003562155A JP2005535562A5 JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5 JP 2003562155 A JP2003562155 A JP 2003562155A JP 2003562155 A JP2003562155 A JP 2003562155A JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- c5ar
- binding
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 25
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 25
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000000440 neutrophil Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 238000013508 migration Methods 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000005482 chemotactic factor Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35096102P | 2002-01-25 | 2002-01-25 | |
| PCT/AU2003/000084 WO2003062278A1 (en) | 2002-01-25 | 2003-01-24 | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009271989A Division JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005535562A JP2005535562A (ja) | 2005-11-24 |
| JP2005535562A5 true JP2005535562A5 (enExample) | 2006-02-23 |
| JP4559081B2 JP4559081B2 (ja) | 2010-10-06 |
Family
ID=27613447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562155A Expired - Lifetime JP4559081B2 (ja) | 2002-01-25 | 2003-01-24 | 抗Ｃ５ａＲ抗体及びその使用 |
| JP2009271989A Expired - Lifetime JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009271989A Expired - Lifetime JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8071096B2 (enExample) |
| EP (2) | EP2371861B1 (enExample) |
| JP (2) | JP4559081B2 (enExample) |
| CN (2) | CN1642983A (enExample) |
| AU (3) | AU2003202297C1 (enExample) |
| CA (1) | CA2476773C (enExample) |
| DK (1) | DK2371861T3 (enExample) |
| ES (2) | ES2646792T3 (enExample) |
| NZ (1) | NZ534399A (enExample) |
| WO (1) | WO2003062278A1 (enExample) |
| ZA (1) | ZA200406347B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003202297C1 (en) | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| US7455837B2 (en) * | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| AU2007288118A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2008109742A1 (en) * | 2007-03-06 | 2008-09-12 | Novo Nordisk A/S | Modulation of complement system activation for treatment of bleeding-related inflammation |
| CA2718588A1 (en) * | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| KR20100117120A (ko) | 2008-02-20 | 2010-11-02 | 지투 인플레메이션 피티와이 엘티디 | 인간화된 항-Ｃ5ａＲ 항체 |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| RU2616881C2 (ru) * | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| PT2888593T (pt) | 2012-08-21 | 2018-12-12 | Janssen Pharmaceutica Nv | Anticorpos contra risperidona e utilizações dos mesmos |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| CN105744996B (zh) * | 2013-11-28 | 2018-10-19 | 通用电气医疗集团生物工艺研发股份公司 | 发酵饮料的稳定 |
| EP3119802B1 (en) * | 2014-03-20 | 2019-12-04 | InflaRx GmbH | Inhibitors of c5a for the treatment of viral pneumonia |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| JP7617012B2 (ja) * | 2019-03-14 | 2025-01-17 | モルフォシス・アーゲー | Ｃ５ａＲを標的とする抗体 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| EP4196501A1 (en) | 2020-08-12 | 2023-06-21 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) * | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) * | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) * | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0832231A2 (en) | 1995-06-05 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| JP2001511645A (ja) | 1997-01-31 | 2001-08-14 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトＣ５ａ様受容体 |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| AU2002231194A1 (en) | 2000-11-07 | 2002-05-21 | Genetics Institute, Llc | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| WO2002059263A2 (en) | 2000-12-19 | 2002-08-01 | Sunol Molecular Corporation | Transgenic animals comprising a humanized immune system |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| EP1438325B1 (en) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AU2003202297C1 (en) | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| AU2004304665B2 (en) | 2003-12-24 | 2009-03-12 | Novo Nordisk A/S | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| JP2010501165A (ja) | 2006-08-22 | 2010-01-21 | ジーツー インフラメイション プロプライエタリー リミテッド | 抗体の作製方法 |
| AU2007288118A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| EP2203180B1 (en) | 2007-10-22 | 2012-11-21 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| KR20100117120A (ko) | 2008-02-20 | 2010-11-02 | 지투 인플레메이션 피티와이 엘티디 | 인간화된 항-Ｃ5ａＲ 항체 |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
-
2003
- 2003-01-24 AU AU2003202297A patent/AU2003202297C1/en not_active Ceased
- 2003-01-24 JP JP2003562155A patent/JP4559081B2/ja not_active Expired - Lifetime
- 2003-01-24 WO PCT/AU2003/000084 patent/WO2003062278A1/en not_active Ceased
- 2003-01-24 US US10/502,145 patent/US8071096B2/en active Active
- 2003-01-24 DK DK10009060.4T patent/DK2371861T3/da active
- 2003-01-24 ES ES10009060.4T patent/ES2646792T3/es not_active Expired - Lifetime
- 2003-01-24 CA CA2476773A patent/CA2476773C/en not_active Expired - Fee Related
- 2003-01-24 NZ NZ534399A patent/NZ534399A/en not_active IP Right Cessation
- 2003-01-24 EP EP10009060.4A patent/EP2371861B1/en not_active Expired - Lifetime
- 2003-01-24 CN CNA038069482A patent/CN1642983A/zh active Pending
- 2003-01-24 CN CN201110205361.6A patent/CN102659945B/zh not_active Expired - Lifetime
- 2003-01-24 EP EP03700693.9A patent/EP1476469B1/en not_active Expired - Lifetime
- 2003-01-24 ES ES03700693.9T patent/ES2561828T3/es not_active Expired - Lifetime
-
2004
- 2004-08-11 ZA ZA200406347A patent/ZA200406347B/en unknown
-
2006
- 2006-01-24 AU AU2006200320A patent/AU2006200320A1/en not_active Abandoned
-
2009
- 2009-11-19 AU AU2009238340A patent/AU2009238340A1/en not_active Withdrawn
- 2009-11-30 JP JP2009271989A patent/JP5202501B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-24 US US13/280,250 patent/US8221757B2/en not_active Expired - Fee Related
-
2012
- 2012-06-15 US US13/525,092 patent/US8673305B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535562A5 (enExample) | ||
| US20250145718A1 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
| KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2009517057A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| EP3683234A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
| JP2011526249A5 (enExample) | ||
| RU2009110154A (ru) | АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ | |
| JP2019505166A5 (enExample) | ||
| JP2019507580A5 (enExample) | ||
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| JP2023537958A (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| US20130274447A1 (en) | Humanized antibodies against cxcr3 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| WO2005060457A2 (en) | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies | |
| CN115368457A (zh) | 抗tigit抗体及其用途 | |
| JP7643727B2 (ja) | 抗－ｆｇｆ１９抗体 | |
| US20170183401A1 (en) | Hypoglycemic agent containing anti-ang2 antibody | |
| HK40049006B (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof | |
| HK40049006A (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof | |
| KR20250143755A (ko) | 종양 괴사 인자 수용체 효능작용 mb | |
| CN116003620A (zh) | 一种结合PD-1和Siglec15的双特异性抗体 | |
| CN115368456A (zh) | 抗pd-1多肽及其用途 | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof |